Janssen to stop further development of JNJ-4178 hepatitis C treatment

Janssen Sciences Ireland has taken a strategic decision to discontinue further development of its investigational regimen JNJ-4178 for the treatment of patients with hepatitis C.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news